Professor Ekuo OKANO of Keio University School of Medicine and colleagues have obtained MHLW approval for clinical studies on allogenic iPS cell-derived neural progenitor cells for the treatment of subacute stage spinal cord injury. They will now investigate the safety and effectiveness by increasing the number of transplanted cells in spinal cord injury in a chronic and a subacute phase. The initial clinical research will be done on 4 patients with 2 million transplanted cells and an observation period of 1 year.
Keio University news release, February 18, 2019
Keio University team to start application of regenerative medicine for subacute spinal cord injury